HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): A. Pieter Kappetein Ad J.J.C. Bogers Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Birim, O. Articles by Bogers, A. J.J.C. Search for Related Content PubMed PubMed Citation Articles by Birim, O. Articles by Bogers, A. J.J.C.

Eur J Cardiothorac Surg 2005;28:759-762
© 2005 Elsevier Science NL

Charlson comorbidity index as a predictor of long-term outcome after surgery for nonsmall cell lung cancer

Department of Cardio-Thoracic Surgery, Erasmus MC Rotterdam, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands

Received 23 March 2005; received in revised form 14 June 2005; accepted 29 June 2005.

^_* Corresponding author. Tel.: +31 10 4635412; fax: +31 10 4633993. (Email: a.kappetein{at}erasmusmc.nl).

Objective: To evaluate the impact of the Charlson comorbidity index on long-term survival in nonsmall cell lung cancer surgery and determine whether this index is a better predictor of long-term survival than individual comorbid conditions. Methods: From January 1989 to December 2001, 433 (340 men, 93 women) consecutive curative resections for nonsmall cell lung cancer were performed. Each patient was preoperatively assessed according to the Charlson comorbidity index. Survival curves were estimated by the Kaplan–Meier method. Risk factors for overall and disease free survival were determined by univariate and multivariate Cox regression analysis. Results: The patients ranged in age from 37 to 82 years, with a mean age of 65 years. Hospital mortality was 3.7%. Five-year overall and disease free survival was 45 and 43%, respectively. Among patients with Charlson comorbidity grade 0, 5-year overall survival was 52%, among patients with Charlson comorbidity grade 1–2 it was 48%, and among patients with Charlson comorbidity grade 3 it was 28%. Univariate analysis showed that male gender, age, congestive heart failure, chronic pulmonary disease, Charlson comorbidity index, clinical stage, pathological stage, and type of resection were significantly associated with an impaired survival. Multivariate analysis showed that age (relative risk, 1.02; 95% confidence interval, 1.01–1.03), Charlson comorbidity grade 1–2 (relative risk, 1.4; 95% confidence interval, 1.0–1.8), Charlson comorbidity grade 3 (relative risk, 2.2; 95% confidence interval, 1.5–3.1), bilobectomy (relative risk, 1.7; 95% confidence interval, 1.2–2.5), pneumonectomy (relative risk, 1.5; 95% confidence interval, 1.1–2.0), pathological stage IB (relative risk, 1.5; 95% confidence interval, 1.1–2.2), IIB (relative risk, 1.9; 95% confidence interval, 1.2–3.0), IIIA (relative risk, 1.9; 95% confidence interval, 1.1–3.1), IIIB (relative risk, 2.8; 95% confidence interval, 1.2–6.8), and IV (relative risk, 12.4; 95% confidence interval, 3.2–48.2), were associated with an impaired survival. Conclusions: The Charlson comorbidity index is a better predictor of survival than individual comorbid conditions in nonsmall cell lung cancer surgery. We recommend the use of a validated comorbidity index in the selection of patients for NSCLC surgery.

Key Words: Charlson comorbidity index • Comorbidity • Lung cancer • Surgery • Survival

This article has been cited by other articles:

				G. Testa, F. Cacciatore, G. Galizia, D. Della-Morte, F. Mazzella, S. Russo, N. Ferrara, F. Rengo, and P. Abete Charlson Comorbidity Index does not predict long-term mortality in elderly subjects with chronic heart failure Age Ageing, November 1, 2009; 38(6): 734 - 740. [Abstract] [Full Text] [PDF]

				M. F. Berry, J. Hanna, B. C. Tong, W. R. Burfeind Jr, D. H. Harpole, T. A. D'Amico, and M. W. Onaitis Risk factors for morbidity after lobectomy for lung cancer in elderly patients. Ann. Thorac. Surg., October 1, 2009; 88(4): 1093 - 1099. [Abstract] [Full Text] [PDF]

				A. Brunelli, A. Charloux, C. T. Bolliger, G. Rocco, J-P. Sculier, G. Varela, M. Licker, M. K. Ferguson, C. Faivre-Finn, R. M. Huber, et al. ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy) Eur. Respir. J., July 1, 2009; 34(1): 17 - 41. [Abstract] [Full Text] [PDF]

				D. I. Gaines, V. Durkalski, A. Patel, and M. H. DeLegge Dementia and Cognitive Impairment Are Not Associated With Earlier Mortality After Percutaneous Endoscopic Gastrostomy JPEN J Parenter Enteral Nutr, January 1, 2009; 33(1): 62 - 66. [Abstract] [Full Text] [PDF]

				L. E. Jones and C. C. Doebbeling Beyond the Traditional Prognostic Indicators: The Impact of Primary Care Utilization on Cancer Survival J. Clin. Oncol., December 20, 2007; 25(36): 5793 - 5799. [Abstract] [Full Text] [PDF]

				C.-Y. Wang, Y.-S. Lin, C. Tzao, H.-C. Lee, M.-H. Huang, W.-H. Hsu, and H.-S. Hsu Comparison of Charlson comorbidity index and Kaplan Feinstein index in patients with stage I lung cancer after surgical resection Eur. J. Cardiothorac. Surg., December 1, 2007; 32(6): 877 - 881. [Abstract] [Full Text] [PDF]

				T.-E. Strand, H. Rostad, R. A M Damhuis, and J. Norstein Risk factors for 30-day mortality after resection of lung cancer and prediction of their magnitude Thorax, November 1, 2007; 62(11): 991 - 997. [Abstract] [Full Text] [PDF]

				D. Trousse, F. Barlesi, A. Loundou, A. M. Tasei, C. Doddoli, R. Giudicelli, P. Astoul, P. Fuentes, and P. Thomas Synchronous multiple primary lung cancer: An increasing clinical occurrence requiring multidisciplinary management J. Thorac. Cardiovasc. Surg., May 1, 2007; 133(5): 1193 - 1200. [Abstract] [Full Text] [PDF]